HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hart, R. G. Search for Related Content PubMed Articles by Hart, R. G.

Secondary Prevention of Stroke in Patients with Atrial Fibrillation

What Every Neurologist Should Know

Department of Medicine (Neurology), University of Texas Health Science Center, San Antonio, Texas USA; Email: hart{at}uthscsa.edu

EXTRACT

THE BOTTOM LINE

The bottom line for neurologists is that atrial fibrillation (AF) patients who have had an ischaemic stroke or transient ischaemic attack (TIA) are at high risk of recurrent stroke and should be treated long-term with adjusted-dose warfarin (target INR = 2.5) for secondary prevention, provided it can be given safely and the blood pressure well controlled. For acute management, give aspirin until therapeutic anticoagulation is achieved. Please glance quickly at the attractive figures and illuminating tables, and then skip to the next article unless you want more detail!

SOME HISTORY

By the early 1980s, it was clear from cohort, case-control and autopsy studies that non-valvular AF (i.e. not associated with mitral valvular disease) was a strong, independent risk factor for ischaemic stroke. Based on the presumed pathogenesis of thrombus forming in relatively static blood in the left atrial appendage and then embolizing to the brain (Fig. 1) ...

[PDF of this article]